Could J.C. Penney Company, Inc. (JCP) Really Become an 18-Bagger?

Page 1 of 2

More than two years ago, activist investor Bill Ackman disclosed he had acquired a 16.5%stake in J.C. Penney Company, Inc. (NYSE:JCP) through his hedge fund, Pershing Square Capital Management.  All in all, he had spent more than $900 million for 39 million common shares, including about 4.15 million options.

By June, 2011, he looked like a genius as the investment had risen more than 50% after J.C. Penney tapped Apple Inc. (NASDAQ:AAPL) operations guru Ron Johnson as its CEO. To be sure, few people seemed more suited to right the beleaguered retailer’s wrongs than Johnson. In addition to creating the Apple retail store concept and helping the outlets exceed $1 billion in annual sales within two years of their debut, Johnson was previously Target Corporation (NYSE:TGT)‘svice president of merchandising.

J.C. Penney Company, Inc. (NYSE:JCP)Unfortunately, the good times didn’t last as J.C. Penney embarked on one of the most ambitious retail turnaround plans ever enacted. After hitting a fresh 52-week high of $43.18 last February, shares have fallen 55%, with the company badly missing expectations for both revenue and earnings per share for three consecutive quarters.

J.C. Penney Company, Inc. (NYSE:JCP) the multibagger?
Even so, just a few months ago and with shares trading near today’s levels, Ackman boldly proclaimed his optimism for the struggling company by stating that his firm could make 15 times its money on the investment. He also claimed that it was the only stock in Pershing’s portfolio capable of such returns. Given Ackman’s cost basis, that would put J.C. Penney’s shares near $350, assuming the company could achieve the feat absent dividends or splits.  When all’s said and done, this means investors who buy now would enjoy a solid 18-bagger from Monday’s close at $19.34 per share.

With those kinds of returns on the line, now might be a great time to dig deeper to see if J.C. Penney deserves a spot in your portfolio. First, let’s see how it stacks up next to two of its most significant publicly traded peers:

J.C. Penney Macy’s (NYSE:M) Dillards
Market Capitalization $4.24 billion $15.31 billion $3.97 billion
Debt-to-Equity Ratio 0.85 1.25 0.41
Current Ratio 1.67 1.37 1.71
Trailing P/E Ratio N.A. 12.00 13.21
Est. Forward P/E Ratio N.A. 10.27 11.80
Dividend Yield N.A. 2.00% 0.20%
Payout Ratio N.A. 22% 3.00%
Return on Invested Capital - 8.10% 10.90% 13.90%
PEG Ratio (5 yr expected) - 0.50 0.88 2.42

Source: Yahoo! Finance.

At first glance, J.C. Penney’s balance sheet looks solid with $525 million in cash and a reasonable debt-to-equity ratio of 0.85. However, we still can’t assign trailing or forward P/E ratios because of brutal losses in each of the last five quarters. In addition, after reporting its first-quarter loss last year, the retailer suspended its $0.20-per-share dividend. While this gave many otherwise patient investors one more reason to jump ship and buy the shares of comparatively rock-solid competitors, it also freed up $175 million per year to be used for financing the planned transformation. Unfortunately, J.C. Penney’s ROIC is currently a dismal -8.10%, reflecting its current inability to create shareholder value by reinvesting that cash in its business.

Finally, because analysts expect earnings to continue declining, the company has a negative PEG ratio of -0.48. This might not be a bad thing if free cash flow showed dramatic improvements as earnings decreased, but significant capital expenditures have helped FCF stay significantly negative in four of the last five quarters.

The turnaround plan
To Ackman’s credit, expectations for J.C. Penney are undeniably low and its stock price reflects that sentiment. Given the unsettling number of N.A.s and negative ratios in the table above, however, it seems investors have every right to be scared.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!